TP is particularly reported to be over-expressed in the prostate cancer, therefore, active compounds against TP were also evaluated for their effect on the proliferation of prostate cancer cells (PC3) using the (3-[4,5-dimethylthiazole-2-yl]-2,5-diphenyl-tetrazolium bromide) MTT colorimetric assay [2, 30, 31]. Here, TYMP is linked to prostate carcinoma.